Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bandwidth Inc (BAND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bandwidth Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Bandwidth Inc trades at $51.42 (market cap $1.66B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 17.8× Bandwidth Inc's market cap, and Bandwidth Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BAND | |
|---|---|---|
Market Cap | $29.60B | $1.66B |
Sector | Health | Technology |
52-Week High | $491.22 | $78.44 |
52-Week Low | $205.48 | $12.82 |
Enterprise Value | $27.56B | $2.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Bandwidth (BAND) trades at $51.97, down 1.4% over 24 hours, with a bullish technical outlook supported by moving averages despite overbought RSI signals. The company reported strong Q2 2026 results, beating EPS estimates with $0.37 versus $0.3652 expected, and raised its full-year outlook on AI-driven demand growth. Revenue climbed 22% year-over-year to $220 million, though net income margins remain thin at 0.27% for 2026.
The stock offers upside to the $75.25 analyst consensus target, fueled by AI adoption and enterprise wins, but risks include high valuation multiples like a 34.08 EV/EBITDA and competitive pressures in cloud communications. Execution on profitability improvements will be critical for sustaining gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bandwidth Inc
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →
